Induced pluripotent stem cells model personalized variations in liver disease resulting from α1-antitrypsin deficiency.
about
Stem cell-derived liver cells for drug testing and disease modelingERAD defects and the HFE-H63D variant are associated with increased risk of liver damages in Alpha 1-Antitrypsin DeficiencyInduced Pluripotent Stem Cells: Global Research Trends.Enhancing Autophagy with Drugs or Lung-directed Gene Therapy Reverses the Pathological Effects of Respiratory Epithelial Cell Proteinopathy.Mapping the Cell-Surface N-Glycoproteome of Human Hepatocytes Reveals Markers for Selecting a Homogeneous Population of iPSC-Derived Hepatocytes.Hepatocyte-like cells derived from induced pluripotent stem cells.A Carboxyl Ester Lipase (CEL) Mutant Causes Chronic Pancreatitis by Forming Intracellular Aggregates That Activate Apoptosis.Hepatic differentiation of human iPSCs in different 3D models: A comparative study.Protocol for Directed Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) to a Hepatic Lineage.Liver cell therapy: is this the end of the beginning?Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions.Modeling Inborn Errors of Hepatic Metabolism Using Induced Pluripotent Stem Cells.Optimized performance of the integrated hepatic cell-loaded cryogel-based bioreactor with intermittent perfusion of acute liver failure plasma.A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia.α1-Antitrypsin deficiency.Pluripotent Stem Cell-Derived Hepatocyte-like Cells: A Tool to Study Infectious Disease.Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
P2860
Q27012605-91C15406-2B8E-4EAD-B61E-90199362EA34Q33803215-722C8A29-ADDE-4327-9E6D-9EE0B0DB27CBQ33914515-DF256C52-390D-4524-AA0F-036D8147040FQ36444154-4652DD29-E805-443D-9D44-B375F95AF38FQ37274206-669C4854-C4F7-40F0-BBA5-913DF5BA6BC5Q38929094-C27E3D18-B28D-49D8-965D-D67302787AA7Q42725781-57E45DC4-3F9C-49AE-A0DC-DE65C620245AQ47137248-B4407C8B-DEBC-4D6C-B2EC-623247856CDDQ48018020-61448DF7-994B-4D89-BF1C-45DB0B117C4AQ48515790-1A0DD050-96AF-4331-90B9-87D296C2FF92Q49167837-6E58ECA0-706C-433D-83F8-0D5275D925D7Q50429584-BD168AF1-1007-4A2A-9C36-91977D74556DQ51026271-0D842677-DE56-42FB-A04E-0F90095FF489Q51067287-97F2D27F-79AF-4704-BE30-3514E7603D57Q51481224-B47F9C81-0BA6-4FEC-9EC4-BC614B7A107EQ55190764-0D58641C-6181-468C-BB8E-C6A61FF345D0Q58407064-3E091424-BD85-46D1-BBD1-12585A2AE056
P2860
Induced pluripotent stem cells model personalized variations in liver disease resulting from α1-antitrypsin deficiency.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Induced pluripotent stem cells ...... rom α1-antitrypsin deficiency.
@en
type
label
Induced pluripotent stem cells ...... rom α1-antitrypsin deficiency.
@en
prefLabel
Induced pluripotent stem cells ...... rom α1-antitrypsin deficiency.
@en
P2093
P2860
P356
P1433
P1476
Induced pluripotent stem cells ...... from α1-antitrypsin deficiency
@en
P2093
Alejandro Soto-Gutierrez
Andrew A Wilson
Carol A Feghali-Bostwick
Darrell N Kotton
David H Perlmutter
Donna B Stolz
Jayanta Roy-Chowdhury
Masaki Nagaya
P2860
P304
P356
10.1002/HEP.27753
P407
P577
2015-04-13T00:00:00Z